Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.

Postorino MC, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Ladisa N, Lapadula G, Lorenzotti S, Sighinolfi L, Castelnuovo F, Di Pietro M, Gotti D, Mazzini N, Torti C; MASTER Study Group.

Open AIDS J. 2016 Jul 15;10:136-43. doi: 10.2174/1874613601610010136. eCollection 2016.

2.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G.

Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. No abstract available.

PMID:
26445966
3.

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.

Postorino MC, Prosperi M, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Saracino A, Costarelli S, Lorenzotti S, Sighinolfi L, Di Pietro M, Torti C; MASTER Study Group.

Clin Microbiol Infect. 2015 Apr;21(4):386.e1-9. doi: 10.1016/j.cmi.2014.10.022. Epub 2014 Nov 11.

4.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group.

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
5.

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.

Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group.

BMC Infect Dis. 2014 Feb 12;14:79. doi: 10.1186/1471-2334-14-79.

6.

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.

PMID:
23719349
7.

A survey of methicillin-resistant Staphylococcus aureus control strategies in Italy.

Pan A, Bombana E, Tura G, Curti C, Lorenzotti S, Mondello P, Patroni A, Tacconelli E, Rigobello V, Signorini L, Vizio M, Goglio A.

Infection. 2013 Aug;41(4):783-9. doi: 10.1007/s15010-013-0454-7. Epub 2013 Apr 1.

PMID:
23543436
8.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study.

Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26.

9.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group.

J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426.

10.

Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.

De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; ICoNA Foundation Study Group.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101. doi: 10.1097/QAI.0b013e318259875b. No abstract available.

PMID:
22728753
11.

Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort.

Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, De Luca A, Cassola G, Vullo V, Carosi G, Antinori A, Tozzi V, Monforte AD; Icona Foundation Study Group.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):163-72. doi: 10.1097/QAI.0b013e31822e57e9.

PMID:
21826011
12.

Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count.

Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'arminio Monforte A; ICONA Foundation Study Group.

AIDS. 2011 Jul 17;25(11):1385-94. doi: 10.1097/QAD.0b013e3283471d10.

PMID:
21505312
13.

Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008.

Prosperi MC, Cozzi-Lepri A, Antinori A, Cassola G, Torti C, Ursitti MA, Pellizzer GP, Giacometti A, d'Arminio Monforte A, De Luca A; Icona Foundation Study Group.

HIV Med. 2011 Mar;12(3):174-82. doi: 10.1111/j.1468-1293.2010.00866.x. Epub 2010 Aug 18.

14.

Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study.

Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, Torti C, Costantini A, Narciso P, Ghinelli F, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group.

Clin Infect Dis. 2010 May 1;50(9):1316-21. doi: 10.1086/651688.

PMID:
20297953
15.

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.

Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group.

AIDS. 2010 Jan 28;24(3):427-35. doi: 10.1097/QAD.0b013e328334344e.

PMID:
19910787
16.

Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.

Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group.

AIDS. 2009 Nov 27;23(18):2485-95. doi: 10.1097/QAD.0b013e3283326879.

PMID:
19898216
17.

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.

Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group.

HIV Med. 2010 Feb;11(2):104-13. doi: 10.1111/j.1468-1293.2009.00750.x. Epub 2009 Sep 1.

18.

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.

d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group.

Clin Infect Dis. 2009 Aug 15;49(4):612-22. doi: 10.1086/603557.

PMID:
19591597
19.

Community-acquired methicillin-resistant Staphylococcus aureus ST398 infection, Italy.

Pan A, Battisti A, Zoncada A, Bernieri F, Boldini M, Franco A, Giorgi M, Iurescia M, Lorenzotti S, Martinotti M, Monaci M, Pantosti A.

Emerg Infect Dis. 2009 May;15(5):845-7. doi: 10.3201/eid1505.081417. No abstract available.

20.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

Supplemental Content

Loading ...
Support Center